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Summary
Purpose: Intracortical microinjection of fluorocitrate, a reversible inhibitor of glial
tricarboxylic acid (TCA), results in impaired glial metabolism and epileptic seizures.
To determine the potential contribution of epileptic activities to the metabolic
properties of fluorocitrate, we investigated the seizure-inducing property of fluor-
ocitrate at different doses.
Methods: Twenty-seven male Sprague Dawley rats (250—400 g) were studied with
chronically implanted electrodes and cannulae in the occipital cortices. A week after
surgery, awake behaving rats were injected with 0.2 ml solution containing various
concentrations of fluorocitrate or saline in the right occipital cortex; two sham-
treated animals did not receive an injection. EEG was recorded with implanted
electrodes. Thionin staining was used to verify injection sites. Twenty rats underwent
immunohistochemistry for glial fibrilary acidic protein (GFAP) and neuronal nuclear-
specific antigen (NeuN) 48 h after the injections.
Results: Seizures developed within an hour of injection in all the rats that received
0.8 nmol fluorocitrate and 2 of 4 rats that received 0.4 nmol fluorocitrate. Five of 12
animals that received 1.2 nmol fluorocitrate experienced status epilepticus. There
was a significant increase in GFAP staining at the injection site in doses 0.8 nmol
fluorocitrate. There was only mild neuronal loss revealed by NeuN staining at the
injection site in the animals that had received 1.6 nmol flourocitrate.
Conclusion: This study shows that fluorocitrate results in focal epileptic seizures with
secondary generalization in a dose-dependent manner, including low doses of this
agent previously used for studies of brain metabolism.
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Epileptic seizures are evolving repetitive rhythmic
discharges associated with behavioral changes1—4
while interictal epileptic spikes (IEDs) are abnormal
hypersynchronous electrical discharges of a popula-
tion of neurons in a small region of the brain with no
or minimal propagation so that they usually do not
alter behavior.5 Electroencephalogram (EEG)
remains the primary tool in the study of epileptic
activities. EEG tracing records the extracellular
electrical field potentials generated by a population
of cortical neurons, which amplifies small changes in
the voltage difference between two inputs electro-
des and displays them continuously with great tem-
poral resolution.6
More than 30 percent of patients with epilepsy
have inadequate control of seizures with drug ther-
apy and are considered to have intractable epilepsy
with recurrent seizures.7 This underlies our limited
understanding of the factors that trigger seizures in
epileptic patients and requires greater attention to
the potential role of the non-neuronal elements of
the nervous system. Astroglial cells play a key role in
energy metabolism and cycling between the inhibi-
tory and excitatory neurotransmitters through glu-
tamate-glutamine-gamma aminobutyric acid
(GABA) shunt.8 The participation of glial cells in
seizure generation is not well known. Fluorocitrate
is a reversible blocker of aconitase in tricarboxylic
acid (TCA) cycle, which preferentially inhibits the
glial TCA cycle and impairs glial metabolism. Fluor-
ocitrate inhibits glial metabolism in in vitro pre-
parations at doses ranging from 5—100 mM.9
Intracerebral injection of fluorocitrate reduces glial
glutamine,10,11 but its effect has been demon-Table 1 Electrographic characteristics of the SD rats in th
Drug No. of animals
per group
Average body
weight (g)
E
Sham-treated animals
(no injection)
2 328.7  22. N
Saline control 3 294.7  23.2 N
FLU 0.2 nmol mM 3 306  12.5 N
FLU 0.4 nmol 4 323  14.5 R
o
FLU 0.8 nmol 3 308  5.7 B
FLU 1.2 nmol 5 302.8  21.6 R
<
1
FLU 1.6 nmol 7 285.7  27 R
<
w
FLU, fluorocitrate, and saline injected in a volume of 0.2 ml; SE, ststrated at a relatively larger volume of about 1 ml
of 1 mM solution (i.e. 1 nmol).12 Even larger
intrathecal volume (i.e. 5 ml of 1 mM or 5 nmol)
and similar systemic doses of fluorocitrate has been
shown to induce seizures.13 Direct spread of flour-
ocitrate in such large volumes may result in loss of
its cellular selectivity. In a previous study,11 seizures
resulted from a high concentration (6.4 mM in
0.125 ml or 0.84 nmol) of fluorocitrate injected
intracortically into the frontal cortex in acute
experiments. However, there are no published data
on the epileptic properties of different doses of
fluorocitrate despite its popularity to study cerebral
metabolism using modern tools such as magnetic
resonance spectroscopy (MRS).9 The purpose of this
study was to determine epileptic property of a fixed
volume of fluorocitrate at various doses. Fluoroci-
trate was injected into the occipital cortex of SD
rats in the present study.Materials and methods
Animal preparations
This study was approved by the University of Wes-
tern Ontario’s Institutional Animal Care and Use
Committee. Twenty-seven adult male Sprague Daw-
ley (SD) rats (Charles River, QE) with body weight
ranging from 250—400 g were housed in a 12 h dark
and 12 h light cycle and had food and water ad
libitum. The animals were anesthetized with
sodium pentobarbital (65 mg/kg, intraparotenially
(IP), MTC Pharmaceuticals, Cambridge, ON) and
atropine methylnitrate (0.12—0.17 mg/kg, IP) was
injected to prevent fluid accumulation in theis study
pileptic activity: duration and onset after injection
one
one
one
ecurrent seizures in 2/4 rats for over 30 min,
nset at 1 h
rief seizures in 3/3 rats for over 1 h, onset at 45 min
ecurrent seizures for over 2 h in 5/5 rats; onset
30 min; 2/5 rats with SE lasting 3 h with onset within
min of injection
ecurrent seizures for over 3 h in 7/7 rats; onset
15 min; 3/7 rats with SE lasting up to 6 h that began
ithin 1 min of injection
atus epilepticus.
A gliotoxin model of seizures 485airway. They were then placed in a stereotaxic
apparatus (David Kopf Instruments, Inc., Tujunga,
CA) to implant 6 EEG electrodes (125 mm diameter
stainless-steel wires electrodes coated with Teflon
except at the tips) and two 27 gauge stainless-steel
canuulae for guiding subsequent infusion by a 33
gauge inner canuula. The animal head was shaved
and scalp incised in order to expose the skull. The
homologous regions of the frontal lobes (B +1.0, L
2.0, D 1.6), hippocampus (B 3.5, L 2.5, D
3.3), and occipital lobes (B 6.0, L 4.0, D 1.6)
were implanted with the electrodes, which were
secured in place with dental cement. Some animals
had additional two electrodes in the parietal (B
0.8, L 4.2, D 1.6) regions. The canuulae were
inserted in the same burr holes as the occipital
electrodes. The coordinates were obtained from a
stereotaxic rat brain atlas.14 The animals were
allowed to recover from the surgery for at least 1
week. Fluorocitrate solutions were prepared
according to a published method15 from DL-fluoro-
citric acid barium salt (F9634, C12H8F2O14Ba3, M.W.
826.16, purity 95%, Sigma—Aldrich Canada Ltd.,
Oakville, ON). There were3 animals in each group,Figure 1 Fluorocitrate induced seizures in an undrugged an
fluorocitrate in the right occipital cortex (RO). Note extensi
hippocampus (RH) as well as prominent spread to the left hipp
are both segments of the same seizure. Referential intracrania
done on a polygraph manufactured by Grass Co. Each small squplus 2 sham-treated rats that underwent the same
surgery but they did not receive any injections
(Table 1). On the day of experiment, 0.2 ml of saline
or 0.2, 0.4, 0.8, 1.2, and 1.6 nmol of fluorocitrate
was injected through the right occipital canuula
1.6 mm below the skull surface using a polyethylene
50 tube attached to a Hamilton microlitre syringe
(72—1742, 0.5 ml volume with a 32 gauge needle,
Harvard Apparatus, Inc., Saint Laurent, QE). The
canuulae in the left occipital lobe were used in two
cases that the right-sided canuulae were blocked.
EEG was recorded by a Grass Instruments Model 8—
10 polygraph or a digital EEG (XLTEK, Oakville, ON)
using a laptop computer. EEG was monitored for
maximum of 6 h (i.e. till the termination of epileptic
discharges) after each injection and again half an
hour per day until their sacrifice 48 h after the
injections. They were then given a bolus of 45%
urethane 1.3 g/kg IP (Sigma—Aldrich Inc., St. Louis,
MO) and perfused transcardially with 100 ml of 0.9%
saline followed by 500 ml of fixative consisting of 4%
freshly depolymerized paraformaldehyde (BDH Inc.,
Toronto, ON) in 0.1 M phosphate buffer (PB, pH 7.4)
using a perfusion pump (Masterflex C/literTM pumpd awake SD rat (240 g) given 0.2 ml of 8 mM (1.6 nmol) of
ve spread to the left occipital cortex (LO) and the right
ocampus (LH), left and right frontal lobes (F). (A) and (B)
l recordings with the reference in the skull and recordings
are represents 1 s in time domain. Sensitivity = 1 mV/Cm.
486 S.M. Mirsattari et al.system, Cole—Parmer Instrument Co., Vernon Hills,
IL) via the left ventricle of the heart for histologic
confirmation of the injection site using thionin stain-
ing and subsequent immunocytochemical examina-
tion.
Immunohistochemistry
Brain of each animal was removed and cryopro-
tected in 18% buffered-sucrose for subsequent his-
tological studies. Coronal sections (40 mm) through
the entire brain were cut on a freezing microtome,
collected in PB, and kept in storage solution con-
taining 30% glycerol, 30% ethylene glycol (Sigma—
Aldrich Inc., St. Louis, MO) in 0.1 M PB at 20 8C.
The injection site and location of the recording
electrodes were verified under the light microscopy
after staining with thionin in all the animals. Three
animals per each dose of fluorocitrate and saline and
the two sham control animals (i.e. n = 20) were
studied with glial fibrilary acidic protein (GFAP)
and a neuronal marker (NeuN) immunostaining.
Briefly, free floating brain sections were removed
from storage solution, washed in 0.1 M PB and then
placed into blocking serum consisting of 10% non-Figure 2 GFAP staining in the same rat shown in Fig. 1 (A an
animal (C and D). (A) and (C): sites of injection, (B) and (D):
injection site (A) only and not in the contralateral site (B). Mimmune normal goat serum (Sigma—Aldrich Inc., St.
Louis, MO) and 0.1% Triton X-100 (Sigma—Aldrich
Inc., St. Louis, MO) in PB for 1 h at room tempera-
ture. After blocking nonspecific bindings, the sec-
tions were incubated in GFAP antibody (rabbit
polyclonal, 1:500, Dakocytomation, Denmark) or
NeuN (mouse monoclonal, 1:20,000, Abcam Inc.,
Cambridge, MA) in PB containing 1% bovine serum
albumin (BSA, Sigma—Aldrich Inc., St. Louis, MO) for
48 h at 4 8C. The sections were washed in PB and
then incubated in biotinylated goat anti-mouse anti-
body at 1:200 (Bio/Can Scientific, Mississagua, ON)
in PB containing 1% BSA for 1 h at room temperature.
The sections were washed in PB and then incubated
in avidin—biotin horseradish peroxidase complex
(ABC Elite; Vector Laboratories, Burlingham, CA)
for 1 h at room temperature. After washing in PB,
they were incubated in the chromogen 3,30-diami-
nobenzidine tetrahydrochloride (DAB; Sigma—
Aldrich Inc., St. Louis, MO) and then hydrogen per-
oxide (0.003%) was added to initiate the peroxidase
reaction. Sections were washed, mounted on
chrome-alum-coated slides, and allowed to air
dry. They were then dehydrated in a series of
ascending alcohols (70%, 95%, 100% twice ford B) 48 h after the injection of fluorocitrate and a control
contralateral sites. Note the reactive astrocytosis at the
agnification 16.
A gliotoxin model of seizures 4872 min each), cleared in xylene for 5 min twice and
coverslipped with Entalan mounting medium (BDH
Inc.). To control for specificity of immunostaining,
some sections were processed as above but without
the primary or secondary antibody. The immunohis-
tochemistry method for NeuN followed previously
published.16 Immunohistochemical labeling was
examined using an Axioskop miscroscope (Zeise)
under transmitted light, images were photographed
and number of NeuN-labeled neurons were quanti-
fied in 200 mm width axial strip of the occipital
cortex using Image J Image Analysis Software
(NIH), while GFAP-labeled cells in this area were
quantified by direct visual counting. Quantitative
data were analyzed using one-way ANOVA followed
by Turkey’s post hoc test with alpha set at 0.05.Figure 3 Higher magnification image showing GFAP-
labeled cells in the occipital cortex of 0.8 nmol fluoroci-
trate-injected rat (bar: 25 mm).Results
All 15 rats injected with 0.8 nmol of fluorocitrate
and 2 of the 4 rats with 0.4 nmol flourocitrate
developed seizures within an hour of the injection,
but none of the 3 rats injected 0.2 nmol of fluor-
ocitrate experienced seizures (Table 1 and Fig. 1).
Two of 5 rats that received 1.2 nmol of fluorocitrate
and 3 of 7 rats that received 1.6 nmol of fluoroci-
trate developed status epilepticus (SE) with violent
motor seizures lasting greater than 1 h and required
diazepam 5 mg/kg IP to terminate the seizures.
These rats developed seizures within 1 min of
injecting fluorocitrate. The average delay to the
onset of the seizures was 30 min. None of the rats
had seizures during the subsequent recording days,
except for the recurrence of a single motor seizure
in one rat 24 h after receiving 0.8 nmol of fluoroci-
trate. There was a dose-dependent increase in the
intensity of the seizures and they frequently
become secondarily generalized. During the sei-
zures, the animals either had motionless stare or
violent jumps and running in circles in the cage.
There were very few IEDs and they were seen with
fluorocitrate doses of0.8 nmol and only within theTable 2 Changes in neuronal and glial numbers quantified i
the occipital cortex adjacent to the injection site
Drug GFAP immunoreac
Saline control 4.8  2.7
Fluorocitrate 0.2 nmol 5.3  4.8
Fluorocitrate 0.4 nmol 8.1  6.2
Fluorocitrate 0.8 nmol 31.4  8.1 *
Fluorocitrate 1.2 nmol 35.7  5.9 *
Fluorocitrate 1.6 nmol 51.8  8.6 *
All values were indicated as themeans  standard error of the numbe
injection site. *p < 0.05 compared with control group.first 6 h of the recording. Sham-treated animals and
those receiving saline injections did not have any
epileptic discharges at any time of the recording.
The injection siteswereverifiedby thionin staining
in all the animals. There was a dose-dependent
significant increase in GFAP staining at the injection
site with enlarged astrocytes that had swollen pro-
cesses in all the study animals that received
0.8 nmol of fluorocitrate (Figs. 2 and 3). Only mini-
mal GFAP staining at the injection site was seen with
0.4 nmol of fluorocitrate but none with 0.2 nmol of
fluorocitrate, saline injection, or sham-treated ani-
mals (Table 2). NeuN staining demonstrated minimal
neuronal loss at the injection site only with the high-
est dose of fluorocitrate (i.e. 1.6 nmol) (Fig. 4).
Otherwise, there was no neuronal loss (Table 2).Discussion
Fluorocitrate induced a dose-dependent epileptic
activity in SD rats. At low doses (0.4—0.8 nmol),n a 200 mm width radial segment of the full thickness of
tive cells NeuN immunoreactive cells
2864.4  186.8
2917.6  369.6
2783.5  258.9
2804.7  164.8
2668.6  203.7
2690.4  348.8
r of immunoreactive cells in the occipital cortex adjacent to the
488 S.M. Mirsattari et al.
Figure 4 NeuN immunostaining in the same rat as in Figs. 1 and 2 48 h after the injection of fluorocitrate. (A) Injection
site and (B) contralateral site. (C) and (D) are higher power views of A and B, respectively. Note mild neuronal loss at the
injection site. Magnification 16.focal seizures with secondary generalization
resulted. At high doses (1.2—1.6 nmol), SE was
found in about half the injected animals. Epileptic
spikes were exceedingly infrequent and seizures
were either associated with motionless stares or
violent motor signs (jumping and running in circles).
This study confirms that glial cells are important in
generating epileptic discharges. Therefore, the
diverse nature of human epilepsy17 and animal
models may be due to varying contributions of the
glia cells and neurons.
Willoughby et al.,11 originally reported that epi-
leptic discharges in the frontal cortex were induced
with local injection of 0.84 nmol of fluorocitrate,
resulting in motor convulsions in 4 of 7 injected rats.
However, Willoughby et al.,11 injected fluorocitrate
under 2% halothane anesthesia, and while the EEG
and behavior were observed after the cessation of
halothane, the surgical procedure and lingering
halothane could have affected the EEG and beha-
vioral responses. By using chronically implanting
electrodes, the present study established that a
lower dose of fluorocitrate induced epileptic dis-
charges and a higher dose induced SE.
The exact mechanisms of glial-mediated seizures
remain to be determined.18 However, extracellularglutamate and potassium (K+), which are normally
cleared by glial cells, are likely important contri-
butors.19—21 Fluorocitrate disrupts glial function and
allows local accumulation of glutamate and K+,
partly derived from normal activity, such that epi-
leptiform activity may arise. Synaptic transmission,
gap junctions, ephaptic transmission, antidoromic
spread, and ionic field potentials22—26 may all play a
role in seizure spread induced by fluorocitrate,
similar to seizures induced by other agents. Future
studies that employ combination of fluorocitrate
and other agents will be valuable in understanding
the interaction of neural and glial elements in gen-
erating, maintaining, and propagating epileptic dis-
charges.
The high incidence of secondarily generalized
seizures and SE in fluorocitrate-induced seizures
demonstrates a potentially important role for the
glial cells in the rapidly propagating seizures, SE,
and medically refractory seizures. There was a
relative paucity of epileptic spikes in the animals
injected with fluorocitrate, which can occur in some
epileptic patients.17 Low doses of fluorocitrate that
do not cause seizure can be used to study early
metabolic changes that may lower seizure thresh-
old. The epileptic properties of flourocitrate
A gliotoxin model of seizures 489demonstrated in this study could have implications
for interpretation of various metabolic studies using
fluorocitrate including those involving MRS. Finally,
the use of flourocitrate to study brain metabolism
should be limited to its non-epileptic doses demon-
strated in this study.Acknowledgement
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